1,108 reports of this reaction
6.6% of all BLINATUMOMAB reports
#1 most reported adverse reaction
PYREXIA is the #1 most commonly reported adverse reaction for BLINATUMOMAB, manufactured by Amgen, Inc. There are 1,108 FDA adverse event reports linking BLINATUMOMAB to PYREXIA. This represents approximately 6.6% of all 16,815 adverse event reports for this drug.
Patients taking BLINATUMOMAB who experience pyrexia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PYREXIA is moderately reported among BLINATUMOMAB users, representing a notable but not dominant share of adverse events.
In addition to pyrexia, the following adverse reactions have been reported for BLINATUMOMAB:
The following drugs have also been linked to pyrexia in FDA adverse event reports:
PYREXIA has been reported as an adverse event in 1,108 FDA reports for BLINATUMOMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PYREXIA accounts for approximately 6.6% of all adverse event reports for BLINATUMOMAB, making it one of the most commonly reported side effect.
If you experience pyrexia while taking BLINATUMOMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.